CA2268022A1 - Galectine 8, 9, 10, et 10sv - Google Patents

Galectine 8, 9, 10, et 10sv Download PDF

Info

Publication number
CA2268022A1
CA2268022A1 CA002268022A CA2268022A CA2268022A1 CA 2268022 A1 CA2268022 A1 CA 2268022A1 CA 002268022 A CA002268022 A CA 002268022A CA 2268022 A CA2268022 A CA 2268022A CA 2268022 A1 CA2268022 A1 CA 2268022A1
Authority
CA
Canada
Prior art keywords
seq
gly
galectin
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002268022A
Other languages
English (en)
Inventor
Jian Ni
Reiner L. Gentz
Steven M. Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2268022A1 publication Critical patent/CA2268022A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)

Abstract

La présente invention concerne de nouvelles protéines de galectine 8, 9, 10 et 10SV faisant partie de la superfamille des galectines. L'invention concerne en particulier des molécules d'acide nucléique isolées codant des protéines de galectine humaine 8, 9, 10 et 10SV. L'invention concerne également des polypeptides de galectine 8, 9, 10 et 10SV, ainsi que des vecteurs, des cellules hôtes et des méthodes de recombinaison permettant leur production. L'invention concerne aussi des méthodes de criblage permettant d'identifier des agonistes et antagonistes de l'activité de la galectine 8, 9, 10 et 10SV. L'invention concerne enfin des méthodes diagnostiques et thérapeutiques.
CA002268022A 1996-10-09 1997-10-09 Galectine 8, 9, 10, et 10sv Abandoned CA2268022A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2809396P 1996-10-09 1996-10-09
US60/028,093 1996-10-09
US9616565 1996-10-09
USPCT/US96/16565 1996-10-09
PCT/US1997/018261 WO1998015624A1 (fr) 1996-10-09 1997-10-09 Galectine 8, 9, 10, et 10sv

Publications (1)

Publication Number Publication Date
CA2268022A1 true CA2268022A1 (fr) 1998-04-16

Family

ID=26703285

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002268022A Abandoned CA2268022A1 (fr) 1996-10-09 1997-10-09 Galectine 8, 9, 10, et 10sv

Country Status (4)

Country Link
EP (1) EP1012266A4 (fr)
JP (1) JP2001501831A (fr)
CA (1) CA2268022A1 (fr)
WO (1) WO1998015624A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062556A1 (fr) * 1998-06-03 1999-12-09 Effector Cell Institute Facteur chimiotactique pour les eosinophiles
CN1302881A (zh) * 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人β－半乳糖苷结合蛋白和编码这种多肽的多核苷酸
US6953658B2 (en) 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
CN1306271C (zh) * 2000-11-01 2007-03-21 株式会社嘉尔药物 癌转移能力检测剂
EP1490403A2 (fr) * 2002-02-28 2004-12-29 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Agents de liaison de glycoproteines cd44 et methodes d'utilisation associees
WO2003074673A2 (fr) * 2002-03-01 2003-09-12 Exelixis, Inc. Lgals tenant lieu de modificateurs de la voie de chk et leurs procedes d'utilisation
CA2505931A1 (fr) * 2002-11-14 2004-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nouvelles sequences de galectine, et compositions et methodes utilisant celles-ci pour traiter ou diagnostiquer l'arthrite et d'autres maladies inflammatoires chroniques
US20060009378A1 (en) 2002-11-14 2006-01-12 Itshak Golan Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
CA2514108A1 (fr) * 2003-01-24 2004-08-05 Galpharma Co., Ltd. Medicaments contenant galectine 9
EP1619203A1 (fr) * 2003-04-28 2006-01-25 Galpharma Co., Ltd. Facteur d'induction de la galectine 9
DE10333406A1 (de) * 2003-07-15 2005-02-10 Protagen Ag T-regulatorische-Zellen enthaltend Galectine zur Therapie und Diagnose von Erkrankungen
EP1685159B1 (fr) * 2003-10-03 2012-08-01 Brigham & Women's Hospital Polypeptides de Tim-3
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
DK1736541T3 (da) * 2004-03-29 2013-05-06 Galpharma Co Ltd Nyt modificeret galectin 9-protein og anvendelse heraf
WO2005121340A1 (fr) * 2004-06-14 2005-12-22 Galpharma Co., Ltd. Nouvelle protéine de modification galectine 8 et utilisation de celle-ci
CN1332030C (zh) * 2005-04-28 2007-08-15 武汉大学 一种真菌半乳糖凝集素蛋白活性的多肽、其编码序列及制备方法和应用
JP2007131540A (ja) * 2005-11-08 2007-05-31 Galpharma Co Ltd Ｃｄ４４機能抑制因子による抗アレルギー薬、免疫抑制薬および抗腫瘍薬
CN102205111B (zh) * 2011-05-19 2013-01-23 武汉大学 杨树菇半乳糖凝集素在制备抗hiv感染药物中的用途
WO2014171018A1 (fr) * 2013-04-20 2014-10-23 株式会社ガルファーマ Procédé permettant de diagnostiquer une maladie (ou des maladies), procédé permettant de traiter ou de prévenir une maladie (ou des maladies), kit permettant de diagnostiquer une maladie (ou des maladies), et médicament permettant de traiter ou de prévenir une maladie (ou des maladies)
JP5420791B1 (ja) * 2013-08-23 2014-02-19 肇 福永 サルモネラ菌及びシート状ｍ細胞
MX2018013683A (es) * 2016-05-10 2019-06-17 Genentech Inc Métodos para disminuir los enlaces de trisulfuro durante la producción recombinante de polipéptidos.
JP7224583B2 (ja) * 2018-01-29 2023-02-20 日本メナード化粧品株式会社 ガレクチン－９産生促進剤
CN108409850A (zh) * 2018-01-30 2018-08-17 河南师范大学 一种鱼源半乳糖凝集素CaGal重组蛋白的制备方法及其应用
CN113999287B (zh) * 2021-12-02 2023-06-27 深圳湾实验室坪山生物医药研发转化中心 一种靶向半乳糖凝集素-10的多肽抑制剂及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
WO1996039419A1 (fr) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Genes et proteines specifiques du colon
WO1997003190A1 (fr) * 1995-07-11 1997-01-30 Sagami Chemical Research Center PROTEINE HUMAINE SEMBLABLE A GALECTINE-4 ET ADNc CODANT CETTE PROTEINE

Also Published As

Publication number Publication date
JP2001501831A (ja) 2001-02-13
EP1012266A1 (fr) 2000-06-28
EP1012266A4 (fr) 2004-04-28
WO1998015624A1 (fr) 1998-04-16

Similar Documents

Publication Publication Date Title
CA2268022A1 (fr) Galectine 8, 9, 10, et 10sv
US7223840B2 (en) Antimicrobial peptide
US8017349B2 (en) Human neuronal attachment factor-1
KR20030096450A (ko) 고사 유도 분자 ⅱ
WO1998015624A9 (fr) Galectine 8, 9, 10, et 10sv
US5942417A (en) CD44-like protein and nucleic acids
WO1998007749A1 (fr) Nouveaux facteurs de croissance humains
US6468768B1 (en) Galectin 9 and 10SV polynucleotides
AU750170B2 (en) Caspase-14 polypeptides
US6232100B1 (en) Cortistatin Polypeptides
WO1996035703A1 (fr) Inhibiteur humain du gene 1 de l'apoptose
WO1998053069A2 (fr) Recepteurs du gdnf
WO1998029438A9 (fr) Polypeptides de cortistatine
US20030166898A1 (en) Myelin oligodendrocyte glycoprotein-like protein (MOGp)
US20070020277A1 (en) Human Oncogene Induced Secreted Protein I
CA2336406A1 (fr) Galectine 11
AU734384B2 (en) Apoptosis inducing molecule II
US6689360B2 (en) Human B-cell translocation genes-2 and 3 antibodies
AU771013B2 (en) Apoptosis inducing molecule II
CA2266425A1 (fr) Genes 2 et 3 de translocation de lymphocytes b humains
WO1998012204A9 (fr) Genes 2 et 3 de translocation de lymphocytes b humains
AU2004202460A1 (en) Apoptosis Inducing Molecule II
CA2402839A1 (fr) Galectine 11

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead